Fresenius Medical Care AG & Co. KGaA (FME) Given a €107.00 Price Target at Sanford C. Bernstein

Sanford C. Bernstein set a €107.00 ($124.42) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. set a €97.90 ($113.84) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Wednesday, August 29th. Barclays set a €87.20 ($101.40) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research report on Friday, September 28th. Berenberg Bank set a €100.80 ($117.21) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Friday, September 28th. Goldman Sachs Group set a €98.00 ($113.95) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Friday, August 24th. Finally, Jefferies Financial Group set a €82.00 ($95.35) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research report on Tuesday, September 25th. Nine investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of €92.77 ($107.87).

ETR:FME opened at €70.10 ($81.51) on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €75.53 ($87.83) and a 52 week high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Recommended Story: Why is insider trading harmful?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply